This study is in progress, not accepting new patients
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Deborah Wong (ucla)Sue Yom (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at University of California Health
- Deborah Wong (ucla)
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 28 research publications - Sue Yom (ucsf)
I am a radiation oncologist who specializes in the treatment of head and neck, lung, and skin cancers. I serve on national guidelines committees outlining the best practices for these cancers. I design clinical trials to improve treatment of these cancers. I give lectures and design courses to help others learn more about how to best treat these cancers.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Clinical Trial Information
- ID
- NCT03040999
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 804 people participating
- Last Updated